Income statement
USD
Annual
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 167M | 156M | 111M | 56M | 62M |
| Gross Profit | 143M | 132M | 90M | 40M | 42M |
| Operating Income | 37M | 33M | 4M | -24M | -29M |
| EBITDA | 45M | 40M | 13M | -18M | 4M |
| Net Income | 85M | 26M | -15M | -34M | 5M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$5.59
-0.09% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
BioDelivery Sciences International, Inc. (BDSI) is a Healthcare stock with a market cap of $577.05M. The stock last traded around $5.59. Baseline metrics include revenue growth of +6.5%, EPS growth of +215.4%, a dividend yield of 0.0%. What stands out right now is revenue +6.5%, EPS +215.4%, free cash flow +62.7% with operating margin 22.3% and ROIC 15.0%. Valuation is more restrained than many high-expectation growth names at P/E 6.8 and price/sales 3.5. Stock Foundry combines BDSI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BDSI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BDSI Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BDSI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$62.0M
+11.4% YoY
FY Net Income
$5.3M
+115.6% YoY
Free Cash Flow
-$38.3M
-46.4% YoY
Revenue Growth
+6.5%
EPS Growth
+215.4%
Gross Margin
86.0%
Net Margin
50.9%
Income statement
USD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Revenue | 167M | 156M | 111M | 56M | 62M |
| Gross Profit | 143M | 132M | 90M | 40M | 42M |
| Operating Income | 37M | 33M | 4M | -24M | -29M |
| EBITDA | 45M | 40M | 13M | -18M | 4M |
| Net Income | 85M | 26M | -15M | -34M | 5M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|
| Cash & Equivalents | 114M | 112M | 64M | 44M | 21M |
| Total Assets | 325M | 240M | 183M | 109M | 88M |
| Total Liabilities | 137M | 132M | 113M | 79M | 79M |
| Shareholder Equity | 188M | 108M | 70M | 30M | 9M |
| Total Debt | 59M | 78M | 59M | 52M | 48M |
| Net Debt | -56M | -33M | -5M | 8M | 26M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
32M
-34.6% YoY
Capital Expenditures
6M
-184.2% YoY
Free Cash Flow
38M
-46.4% YoY
Key ratios
Gross Margin
86.0%
Operating Margin
22.3%
Net Margin
50.9%
ROE
57.3%
Debt / Equity
0.31x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.